HHS Regulatory Agenda Omits Drug Pricing Actions – Unless OTC Switches Still Count

The US Department of Health and Human Services' list of regulatory priorities for 2018 includes one notable omission: there is no agenda item that focuses on addressing prescription drug costs.

The Trump Administration used the annual update to the federal regulatory agenda as an opportunity to reinforce the de-regulatory theme of the White House, and had all cabinet departments include a narrative statement of priorities along with the list of pending rules. HHS’ Dec. 14